Group 1 - The H1 2025 interim results of DSV A/S are expected to be released on 31 July 2025 at 11:00 am CEST [1] - A webcast and conference call will be held to present the H1 2025 Interim Financial Report, followed by a Q&A session [1] - Participants wishing to ask questions during the conference call must register in advance and will receive dial-in information via email [2] Group 2 - Contact information for Investor Relations is provided, including names and telephone numbers for Stig Frederiksen and Alexander Plenborg [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確性及完整性亦不 發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 AMS PUBLIC TRANSPORT HOLDINGS LIMITED 進智公共交通控股有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 77) 截至二零二五年三月三十一日止年度 五年三月三十一日止年度 全年業績公佈 進智公共交通控股有限公司（「本公司」）董事會（「董事會」）欣然宣佈本公司及其附屬公司（統稱「本 集團」）截至二零二五年三月三十一日止年度之綜合業績，連同截至二零二四年三月三十一日止年度之比較 數字如下： 綜合收益表 | | | 截至三月三十一日止年度 | | | --- | --- | --- | --- | | | 附註 | 二零二五年 | 二零二四年 | | | | 千港元 | 千港元 | | 收益 | 4 | 415,029 | 393,686 | | 直接成本 | | (338,570) | (323,036) | | 毛利 | | 76,459 | 70,650 ...

September 2023 Investor Presentation Cautionary Statement Regarding Forward-Looking Statements This presentation, as well as other statements we make, contains "forward-looking statements" within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as "expect," "may," "can," "believe," "predict," "plan," "potential," "projected," "projections," "forecast," "estimate," "intend," "anticipate," "ambition," "goal," "targ ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 之 任 何 損 失 承 擔 任 何 責 任。 Shun Wo Group Holdings Limited – 1 – 截 至2025年3月31日 止 年 度 之 年 度 業 績 公 告 汛 和 集 團 控 股 有 限 公 司（「本 公 司」）董 事（「董 事」）會（「董 事 會」）欣 然 提 呈 本 公 司 及 其 附 屬 公 司（統 稱「本 集 團」）截 至2025年3月31日 止 年 度（「回 顧 年 度」） 之 經 審 核 年 度 綜 合 財 務 業 績，連 同 截 至2024年3月31日 止 年 度 同 期 之 比 較 數 字。 綜 合 損 益 及 其 他 全 面 收 益 表 截 至2025年3月31日 止 年 度 | | | | | | | | | | | ...

Core Viewpoint - Microsoft is undergoing significant layoffs, with reports indicating that thousands more employees could be let go, particularly in sales, marketing, and gaming divisions, following previous rounds of layoffs earlier in the year [1][3][9]. Layoff Details - In mid-May, Microsoft announced the termination of over 6,000 employees, including 1,985 in Washington, followed by an additional 305 layoffs in early June [2][8]. - The upcoming layoffs are expected to focus heavily on sales and marketing roles, with specific cuts anticipated in the gaming division [3][9]. Employee Sentiment - The impersonal nature of the layoffs, conducted via mass conference calls and email notifications, has created anxiety among remaining employees, leading to speculation about their job security [4][5]. - Employees have expressed concerns about the lack of communication from management regarding layoffs, with many relying on news reports and peer discussions for information [4][5]. Industry Context - Traditionally, tech workers, especially software engineers, were considered safe from layoffs; however, the shift towards artificial intelligence is disrupting this trend [6][7]. - The layoffs are part of a broader strategy to streamline operations and flatten management layers, rather than being performance-based [7]. Impact on Gaming Division - The gaming division has faced multiple rounds of layoffs since the acquisition of Activision Blizzard, with significant job cuts occurring in 2024 [9]. - In the fiscal year ending June 2024, the gaming division generated $21.5 billion in revenue, a notable increase from $15.4 billion the previous year, despite ongoing challenges in Xbox hardware sales [10][11].

Company Overview - FTAI Aviation Ltd. focuses on owning and maintaining commercial jet engines, particularly CFM56 and V2500 engines [5] - The company offers a proprietary portfolio of products, including the Module Factory and a joint venture for manufacturing engine PMA, which provides cost savings and flexibility to its customers [5] - FTAI also owns and leases jet aircraft, facilitating the acquisition of engines at attractive prices, and invests in aviation assets and aerospace products that generate strong and stable cash flows with potential for earnings growth and asset appreciation [5] Upcoming Financial Results - FTAI plans to announce its financial results for the second quarter of 2025 after the closing of Nasdaq on July 29, 2025 [1] - A conference call will be hosted by management on July 30, 2025, at 8:00 A.M. Eastern Time, accessible through registration [2] - A simultaneous webcast of the conference call will be available to the public on a listen-only basis, with a replay available from July 30, 2025, after 11:30 A.M. until August 6, 2025 [3]

Core Insights - McCormick & Company reported a 1% increase in net sales for Q2 2025, driven by volume growth, despite a 1% unfavorable impact from currency fluctuations [5][7][12] - The company reaffirmed its fiscal 2025 outlook, maintaining expectations for net sales, adjusted operating profit, and adjusted earnings per share [5][11][14] Financial Performance - Total net sales for Q2 2025 were $1.66 billion, compared to $1.64 billion in Q2 2024, with organic sales growth of 2% attributed to volume and product mix [5][7][36] - Operating income increased to $246 million in Q2 2025 from $234 million in the same period last year, with adjusted operating income rising to $259 million [5][9][36] - Earnings per share (EPS) for Q2 2025 was $0.65, down from $0.68 in Q2 2024, while adjusted EPS remained stable at $0.69 [10][36] Segment Performance - The Consumer segment net sales rose by 3% to $931 million, with organic sales also increasing by 3% [12][13] - The Flavor Solutions segment saw a 1% decline in net sales to $729 million, with organic sales remaining flat year-over-year [12][13] Cost Management and Outlook - The company is implementing plans to mitigate tariff-related costs and is focused on growth investments to expand operating margins [3][14] - McCormick's fiscal 2025 outlook anticipates net sales growth of 0% to 2%, with adjusted operating income growth of 3% to 5% [15][27] Strategic Initiatives - The Comprehensive Continuous Improvement (CCI) program is driving cost savings and operational efficiencies, contributing to improved margins [9][11] - The company is prioritizing investments in key categories to sustain strong volume trends and long-term profitable growth [11][14]

Core Insights - ProFound Therapeutics has announced a four-year collaboration with Novartis to develop novel therapeutics for cardiovascular disease using its ProFoundry™ Platform [1][3] - The collaboration includes $25 million in upfront and near-term milestone payments, with potential downstream milestone payments of $750 million per target [1][3] Company Overview - ProFound Therapeutics focuses on discovering proteins within the expanded human proteome to develop first-in-class medicines for various diseases [4] - The ProFoundry™ Platform integrates multi-layered biological data and advanced computational tools to identify and validate novel proteins as drug targets [2][4] Collaboration Details - The partnership aims to leverage ProFound's capabilities in identifying novel proteins and Novartis' expertise in cardiovascular drug development [1][3] - The collaboration is expected to accelerate the discovery of new therapeutic targets and support the development of transformative therapies for cardiovascular diseases [3]

Core Viewpoint - Nature's Sunshine Products, Inc. is conducting a secondary public offering of up to 2,854,607 shares at a price of $12.00 per share, with the offering expected to close on June 27, 2025 [1][2]. Group 1: Offering Details - The Selling Stockholder, Fosun Pharma USA, Inc., will receive all net proceeds from the offering, while Nature's Sunshine will not sell any shares or receive any proceeds [2]. - The Company has agreed to potentially purchase up to $15.0 million of its common stock from the underwriters as part of its share repurchase program, but there is no guarantee that any shares will be purchased [3]. - D.A. Davidson & Co. is acting as the sole book-running manager for the offering, which is made under a shelf registration statement filed with the SEC [4]. Group 2: Company Background - Nature's Sunshine Products is a leading manufacturer of herbal and nutritional supplements, distributing products in over 40 countries and ensuring high quality through its own manufacturing facilities [8].

71% objective response rate (ORR) (12/17) per RECIST v1.1, with a favorable safety profile 83% ORR (10/12) in patients across doses selected for ongoing dose expansion study Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Updated results to be presented at ESMO GI on July 2nd Company to host investor event on July 8th ROCKVILLE, Md., June 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision i ...